中国抗体技术出海提速：百奥赛图RenMab获日本专利

Group 1 - The core viewpoint of the news is that Baiaosaitu's RenMice platform has received a significant patent certification in Japan, enhancing its global intellectual property protection and creating a competitive advantage for international expansion [1][3]. - The RenMice platform utilizes unique large fragment chromosome engineering technology to replace mouse antibody genes with human counterparts, allowing for the production of fully human antibodies that maintain natural diversity [1]. - Baiaosaitu has established licensing partnerships with approximately 20 pharmaceutical companies, including Merck, Johnson & Johnson, and BeiGene, leading to rapid growth in its antibody discovery business, with projected revenue of 318 million yuan in 2024, an increase of over 80% year-on-year [2]. Group 2 - Following the patent certification in Japan, Baiaosaitu's overseas market growth potential is expected to expand further, with patents already granted in about 8 countries, including the US, and nearly 40 patent applications under review in 15 countries and regions [3]. - The company is advancing its IPO process on the Sci-Tech Innovation Board and is currently in the inquiry stage, aiming for a dual listing in both A-share and H-share markets, which could position it alongside other major players in the domestic model organism sector [4].